Abstract
Therapeutic nuclear medicine has grown rapidly as a treatment modality in oncology in last decade. A variety of specific tumor-seeking radiopharmaceuticals have been commercialized for radiotherapy. However, most of these therapeutic radiopharmaceuticals are not applied to patients clinically in Taiwan because of difficulty in importing these drugs from other countries and their high expense .Therefore, the Institute of Nuclear Energy Research(INER)in Taiwan has been putting their efforts on developing these therapeutic radiopharmaceuticals and several lands of therapeutic radiopharmaceuticals have been developed successfully in the past few years.90Y-lipiodol,188Re-lipiodol and 188Re-microsphere are developed for the therapy ofhepatoma,188Re-HEDP for metastatic bone pain and188Re-sulfur colloid for malignant ascites. Pre-clinical studies of these radiopharmaceuticals are being carried out and clinical trials will be conducted soon.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
